Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns
1 min read
The story
Cantor Fitzgerald lowered its price target on Regeneron (REGN), pointing specifically to concerns around Eylea (aflibercept), the blockbuster anti-VEGF treatment for wet AMD and other retinal conditions that has historically been one of Regeneron's largest revenue contributors. The downward revision reflects Wall Street's growing unease about Eylea's near-term revenue trajectory as biosimilar competition intensifies and rival therapies like Vabysmo (faricimab) continue to take market share.
Regenerons FY2025 revenue base sits at $14.3B, growing just 1.0% YoY — a deceleration that already hints at the Eylea erosion thesis playing out. Net margins are at 31.4% with diluted EPS of $41.48, so the underlying business remains profitable, but flat top-line growth is a red flag when the stock still carries a meaningful premium to the broader market.
The second-order question is whether Eylea HD (8mg aflibercept) can serve as a credible bridge product — Regeneron has been pushing the higher-dose version to retain patients and physicians ahead of biosimilar AFL entries. Bulls argue the HD formulation and Dupixent's explosive growth trajectory provide enough offset; bears point to the 1% revenue growth figure as evidence the transition is already grinding.
What to watch: the pace of biosimilar AFL market share gains, Vabysmo script trends, and any Dupixent guidance updates that could either offset or underscore the Eylea drag. A soft next earnings print on Eylea net revenue would validate the bear case and likely spark further PT cuts across the street.
The case — both sides
Dupixent's sustained double-digit growth trajectory and the Eylea HD 8mg formulation provide credible revenue offsets, and at a 31.4% net margin with $41.48 EPS, the company generates substantial cash that could support buybacks underpinning the share price.
FY revenue growth of just 1.0% YoY — combined with a fresh Cantor PT cut citing Eylea specifically — suggests biosimilar and competitive erosion is already flowing through the income statement, and the market may not yet have fully re-rated the stock for a structurally slower growth profile.
The house read
Leans bearREGN faces a PT cut from Cantor on Eylea concerns — the question is whether Eylea HD and Dupixent growth can offset biosimilar erosion before the 1% top-line growth rate becomes a consensus re-rating event.
Wrong ifA strong Dupixent beat or surprise Eylea HD script acceleration at the next earnings print could quickly invalidate the short and push the stock higher; any M&A or partnership headline would also be a sharp pain trade.
Published read · research, not advice